About
Julie brings operational experience from biotechnology and healthIT and currently sits on the board of Protagonist Therapeutics (PTGX). Julie has also worked closely with and observed on the boards of CytomX, Labrys Biologics, Dermira, ALDEA Pharmaceuticals, Chrono Therapeutics, and Glooko. The San Francisco Business Times named Julie to the 40 Under 40 Class of 2017 in recognition of her contributions to Bay Area business. Prior to Canaan, Julie worked at Genentech in a variety of positions spanning marketing, development, and business development. This included creating commercial brand plans, forecasting, and recommending modifications to Phase III trials designs for marketed and pipeline oncology products. She advises a number of digital health and BioPharma companies on business development and go to market strategy. Personally, Julie has a particular passion for consumer access and affordability to care. Julie holds an MBA from Stanford's Graduate School of Business, where she
Position in the VCSift Database
- • 11 investors at Canaan Partners are tracked.
- • 626 investors hold the General Partner role in VCSift. Julie Papanek Grant is one of them.
- • 557 investors are based in Menlo Park, California, United States.
Data sourced from 410,343 investor profiles. Updated June 2026.
Investment Focus
- Location
- Menlo Park, US
Contact Information
Find more investors like Julie
Search Investors